Literature DB >> 33917832

Activated Regulatory T-Cells, Dysfunctional and Senescent T-Cells Hinder the Immunity in Pancreatic Cancer.

Shivan Sivakumar1,2,3, Enas Abu-Shah2,4, David J Ahern2, Edward H Arbe-Barnes5, Ashwin K Jainarayanan2,6, Nagina Mangal7, Srikanth Reddy8, Aniko Rendek9, Alistair Easton1, Elke Kurz2, Michael Silva8, Zahir Soonawalla8, Lara R Heij10,11, Rachael Bashford-Rogers12, Mark R Middleton1,3,13, Michael L Dustin2.   

Abstract

Pancreatic cancer has one of the worst prognoses of any human malignancy and leukocyte infiltration is a major prognostic marker of the disease. As current immunotherapies confer negligible survival benefits, there is a need to better characterise leukocytes in pancreatic cancer to identify better therapeutic strategies. In this study, we analysed 32 human pancreatic cancer patients from two independent cohorts. A multi-parameter mass-cytometry analysis was performed on 32,000 T-cells from eight patients. Single-cell RNA sequencing dataset analysis was performed on a cohort of 24 patients. Multiplex immunohistochemistry imaging and spatial analysis were performed to map immune infiltration into the tumour microenvironment. Regulatory T-cell populations demonstrated highly immunosuppressive states with high TIGIT, ICOS and CD39 expression. CD8+ T-cells were found to be either in senescence or an exhausted state. The exhausted CD8 T-cells had low PD-1 expression but high TIGIT and CD39 expression. These findings were corroborated in an independent pancreatic cancer single-cell RNA dataset. These data suggest that T-cells are major players in the suppressive microenvironment of pancreatic cancer. Our work identifies multiple novel therapeutic targets that should form the basis for rational design of a new generation of clinical trials in pancreatic ductal adenocarcinoma.

Entities:  

Keywords:  CD39; ICOS; TIGIT; immune checkpoints; pancreatic cancer; regulatory T-cells; senescent T-cells

Year:  2021        PMID: 33917832     DOI: 10.3390/cancers13081776

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  5 in total

1.  Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry.

Authors:  Thomas P Brouwer; Natasja L de Vries; Tamim Abdelaal; Ricki T Krog; Zheng Li; Dina Ruano; Arantza Fariña; Boudewijn P F Lelieveldt; Hans Morreau; Bert A Bonsing; Alexander L Vahrmeijer; Frits Koning; Noel F C C de Miranda
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

Review 2.  Chemokine Receptor-Targeted Therapies: Special Case for CCR8.

Authors:  Bernhard Moser
Journal:  Cancers (Basel)       Date:  2022-01-20       Impact factor: 6.639

3.  Platelet-Vesicles-Encapsulated RSL-3 Enable Anti-Angiogenesis and Induce Ferroptosis to Inhibit Pancreatic Cancer Progress.

Authors:  Yiyin Zhang; Zhengze Huang; Jiaxi Cheng; Haoqi Pan; Tianyu Lin; Xuqiu Shen; Wenchao Chen; Qi Chen; Chenhui Gu; Qijiang Mao; Yuelong Liang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-24       Impact factor: 6.055

Review 4.  Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy.

Authors:  Daijun Wang; Yanmei Gu; Xin Yan; Chengdong Huo; Guan Wang; Yang Zhao; Muzhou Teng; Yumin Li
Journal:  Front Oncol       Date:  2022-03-30       Impact factor: 6.244

5.  Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study.

Authors:  Laura Miotke; Christopher Nevala-Plagemann; Jian Ying; Vaia Florou; Benjamin Haaland; Ignacio Garrido-Laguna
Journal:  BMC Cancer       Date:  2022-10-12       Impact factor: 4.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.